Pharmaceutical Research Journal Joins Elite Indexing Ranks With Rising Impact Factor

The Journal of Pharmaceutical Investigation, a peer-reviewed publication devoted to pharmaceutical sciences and drug development research, has reached a milestone that matters deeply to researchers, editors, and institutions alike: its inclusion in Science Citation Index Expanded, known widely as SciSearch, beginning in 2021. Alongside this indexing achievement, the journal recorded an Impact Factor of 5.5 for 2022, placing it in the first quartile of its field at position 48 out of 278 journals in the Pharmacology and Pharmacy category. For a journal that has long served the pharmaceutical research community, these developments mark a significant elevation in visibility and standing within the global scientific publishing landscape.

To understand why indexing in Science Citation Index Expanded carries such weight, it helps to consider what the database actually represents. Maintained by Clarivate, the Science Citation Index Expanded is one of the core components of the Web of Science, the citation ecosystem that underpins the Journal Impact Factor, one of the most scrutinized metrics in academic publishing. Journals are not simply admitted to the index; they must pass through a rigorous evaluation process that examines editorial rigor, publishing timeliness, international diversity among authors and editors, citation behavior, and the overall scholarly contribution of the published work. Inclusion signals to researchers that a journal has met internationally recognized standards of quality and that its articles will be discoverable, citable, and counted in the citation networks that shape modern scientific communication.

The timing of the journal’s admission matters as well. Coverage beginning in 2021 means that articles published from that year onward are tracked in the index, allowing citations to accumulate and, after the standard waiting period, contributing to the Impact Factor calculations released annually. The 2022 Impact Factor of 5.5 reflects the frequency with which articles published in 2020 and 2021 were cited during 2022, normalized across the number of substantive research items the journal published in that window. A value of 5.5 is a strong result in pharmacology, a field where citation patterns are often concentrated in a small number of high-profile journals. Reaching a figure of this magnitude shortly after entering the index is notable, because new entrants typically take several years to build the citation base needed for competitive Impact Factors.

Equally significant is the journal’s position within its category. The Web of Science ranks journals in each subject category both by raw Impact Factor and by percentile, dividing them into quartiles designated Q1 through Q4. Ranking 48th out of 278 journals in Pharmacology and Pharmacy places the Journal of Pharmaceutical Investigation in Q1, the top quartile, roughly the top 17 percent of journals in the category. Many universities, funding agencies, and research assessment exercises treat Q1 status as a benchmark of excellence, and publishing in Q1 journals can influence hiring decisions, grant evaluations, and institutional rankings. For authors weighing where to submit their work, the combination of indexing, a healthy Impact Factor, and Q1 ranking makes the journal a considerably more attractive destination than it was before these achievements.

The mechanics behind these numbers deserve a closer look, because they illuminate how scientific reputation is quantified. The Impact Factor, despite its limitations and the ongoing debate about the role it should play in research assessment, remains the single most requested journal metric worldwide. It is computed by dividing the number of citations in a given year to items published in the journal during the preceding two years by the number of citable items, typically articles and reviews, published in those same two years. Distinguishing between citable and non-citable items, such as editorials, letters, and news pieces, is a frequent source of confusion and contention, but the underlying idea is straightforward: the metric aims to capture the average annual citation rate of a journal’s core scholarly output. A journal that publishes clinically and scientifically relevant work in drug development, formulation, pharmacokinetics, and therapeutic evaluation tends to attract steady citation attention from both academic and industry-affiliated researchers.

For the pharmaceutical research community specifically, the value of robust indexing extends beyond prestige metrics. Pharmaceutics and pharmacology are deeply interdisciplinary fields in which academic laboratories, hospital pharmacists, regulatory scientists, and industrial researchers all draw on the same literature. When a journal is comprehensively indexed in Science Citation Index Expanded, its articles become systematically searchable through Web of Science interfaces and through the many discovery platforms that build on its data. Systematic reviews, meta-analyses, and evidence syntheses, all of which are central to evidence-based pharmacotherapy, depend on comprehensive retrieval of relevant studies. Gaps in indexing can mean that important research is overlooked in these syntheses, so broad coverage benefits not just the journal but the accuracy and completeness of the scientific record as a whole.

The journal’s subject scope explains much of its appeal to contributors and readers. Publications of this kind typically cover investigations spanning drug delivery systems, pharmacokinetics and pharmacodynamics, clinical pharmacy practice, pharmaceutical technology, and therapeutic outcomes, providing a venue for work that bridges laboratory formulation science and clinical application. Research of this type sits at the intersection of chemistry, biology, medicine, and engineering, and its readership spans hospital pharmacies, academic departments of pharmaceutics, regulatory bodies, and pharmaceutical companies. A journal serving such a broad community has a strong incentive to maximize discoverability, since potential authors and readers are distributed across many countries and many professional settings. Indexing in the major citation databases is the most direct route to that visibility, and the Q1 ranking now makes the journal competitive for submissions that might previously have gone to longer-established titles.

It is also worth situating this achievement within broader trends in scholarly publishing. The pharmaceutical sciences have expanded dramatically over the past two decades, driven by biologics, novel drug delivery platforms, nanomedicine, and the growing importance of pharmacoeconomics and health outcomes research. This expansion has multiplied the number of journals competing for high-quality submissions, intensifying pressure on editors to demonstrate quality through metrics. At the same time, the research community and major funders have increasingly questioned overreliance on the Impact Factor, promoting alternatives such as article-level citation measures, preprint visibility, and responsible research assessment frameworks. Even so, indexing status and quartile rankings continue to function as practical gatekeepers in the day-to-day decisions of authors, librarians, and evaluators, which is why a journal’s successful entry into the Science Citation Index Expanded and its attainment of Q1 status remain genuinely newsworthy events for its community.

Looking ahead, the journal’s trajectory will depend on sustaining the editorial standards and citation performance that earned its current standing. Early Impact Factors can be volatile, and consolidating a Q1 position requires consistent publication of work that other researchers find useful and citable. If the journal maintains the quality and breadth that accompanied its 2021 indexing and its 2022 Impact Factor of 5.5, it is well positioned to strengthen its role as a reference point for pharmaceutical investigation internationally. For now, the combination of Science Citation Index Expanded coverage, a solid Impact Factor, and a top-quartile category ranking represents a clear vote of confidence from the bibliometric infrastructure that helps determine which journals the global research community reads, cites, and trusts.

Subject of Research: Abstracting and indexing of the Journal of Pharmaceutical Investigation in Science Citation Index Expanded and its 2022 Impact Factor of 5.5 with Q1 ranking in Pharmacology and Pharmacy

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Science Citation Index Expanded, SciSearch, Web of Science, Impact Factor, Q1 journal, Pharmacology and Pharmacy, journal indexing, citation metrics, pharmaceutical sciences, Clarivate, scholarly publishing